Report Published: "China Pharmaceuticals and Healthcare Report Q1 2015"

Improvements in intellectual property protection, an aging population and increasing access to healthcare will drive the robust growth of China's pharmaceutical market. This will attract foreign drug manufacturers despite the downside risks of pharmaeconomics and the government's crackdown on illegal practices .

Headline Expenditure Projections

* Pharmaceuticals: CNY532.4bn (USD86.6bn) in 2013 to CNY616.1bn (USD100.6bn) in 2014; +15.7% in local currency and +16.1% in US dollar terms.
* Healthcare: CNY3 ,230.8bn (USD525.4bn) in 2013 to CNY3,733.1bn (USD609.2bn) in 2014; +15.6% in local currency terms and +15.9% in US dollar terms. For ecast has been upgraded from Q414 due to upgraded growth in private health expenditure.

Full Report Details at
- http://www.fastmr.com/prod/924125_china_pharmaceuticals_and_healthcare_report_q1.aspx?afid=301

Risk/Reward Index

China's Pharmaceutical Risk/Reward Index (RRI) score for Q414 is 64.4 out of the maximum 100 in our newly improved RRI system . The country scored above average for the majority of the indicators and sub-indicators, including overall market expenditure, sector value growth, patent respect and policy continuity. In this quarter, the country is ranked sixth, behind Hong Kong but in front of Singapore in the 19 key Asia Pacific markets.

Key Trends And Developments

* In September 2014, the Lancet Diabetes and Endocrinology published a series of studies that highlight the diabetes epidemic in the country. From less than one percentage of Chinese adults with diabetes previously, approximately 12% of Chinese adults now have diabetes, or 113.9mn in 2010. This has strong implications for diabetes-related health complications such as cardiovascular disease.
* GlaxoSmithKline's China scandal came to an end in September 2014. The company was fined GBP297mn and the company's former China head deported back to the UK.
* In October 2014, the Beijing Post reported that the loosening of the one-child policy has led to a spike in babies born. With the number of newborns expected to increase by 40,000 to...

The China Pharmaceuticals and Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's China Pharmaceuticals and Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Chinese pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for China to test other views - a key input for successful budgeting and strategic business planning in the Chinese pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Malaysia Pharmaceuticals & Healthcare Report Q1 2015
- Peru Pharmaceuticals & Healthcare Report Q1 2015
- Lebanon Pharmaceuticals & Healthcare Report Q1 2015
- Oman Pharmaceuticals & Healthcare Report Q1 2015
- Turkey Pharmaceuticals & Healthcare Report Q1 2015